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Pro-urokinase is a single chain , precursor form of two
chain, 54,000 M r urokinase. Although originally iso-
lated from urine, pro-urokinase is also found in blood,
where it is believed to participate in natural fibrinolysis
alongside tissue plasminogen activator (t-PA). These two
plasminogen activators share the property of inducing
fibrin-selective plasminogen activation, but many of their
other properties, including their modes of action, are
dissimilar. A comparison of some of the clinically rele-
vant properties of pro-urokinase and t-PA is provided.
A multicenter, dose-finding clinical trial of native pro-
urokinase is underway in the United States and in West
Germany. At the time of this writing , 110 patients with
angiographically proved acute coronary thrombosis have
been treated. The findings from one center are sum-
marized in some detail and the overall experience is
reviewed. Preliminary evidence for a potentiating effect
on pro-urokinase-induced thrombolysis by urokinase is
presented. The findings suggest that a bolus of urokinase
(200,000 IV) at the outset increases the reperfusion rate
from 60 to > 80% and shortens the lysis time from ahout
Currently avail able plasminogen activators, streptokinase
and urokinase , are effective thrombolytic agents that have
been on the market in this country for 10 years but have
not enjoyed much popularity . Each activator induces he-
mostatic abnormalities that are related to the systemic ac-
tivation of plasminogen . The resultant hemorrhagic diathesis
has been sufficiently troublesome to clinicians so as to se-
riously limit the use of these agent s. Concern for safety,
rather than efficacy, has therefore been the principal obstacle
to thrombolytic therapy .
By contrast to the effects of strept okinase and urokinase ,
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50 to 30 minutes. A modest (19%) but significant (p <
0,05) decrease in fibrinogen accompanied thrombolysis
by urokinase/pro-urokinase. Nonetheless, significant
bleeding complications in the multicenter study have, to
date , not been encountered and it is suggested that this
rna}' he related to pro-urokinase's sensitivity to inacti-
vation hy thrombin and lack of potentiation by heparin.
Some in vitro data are summarized that provide an
explanation for the potentiating effect of urokinase, the
mechanism for which is believed to be similar to that by
which synergism between t-PA and pro-urokinase has
been postulated to occur. Evidence is reviewed that in-
dicates that pro-urokinase and t-PA induce thrombolysis
far more efficiently when they are combined than when
each is used alone. The findings suggest that a bolus of
t-PA, in place of urokinase, followed by an infusion of
pro-urokinase may be optimaJ because t-PA is more ef-
fective in triggering lysis and pro-urokinase is more re-
active after fibrinolysis has started.
(l Am Coll Cardiol 1987;1O:16B-21B)
spontaneous fibrinoly sis, which can be stimulated by vig-
orous exercise . cuff occlusion or other measures that induce
release of tissue plasmino gen activator , is highly fibrin spe-
cific and efficient (1-3) . Therefore , nature ' s design for in-
duc ing clot lysis serves as a good model to be emul ated by
therapeutic thrombolysis. The two natural activators of fI-
brinolysis that have been isolated from blood are tissue
plasminogen activator (t-PA) (4) and pro-urokinase (5) .
Thanks to modem cell culture methods and recomb inant
DNA technology, both of these activators have been made
available in sufficient quantities to allow for their clinical
evaluation , and much information on recombinant t-PA
(rt-PA) has already been published. Experience with pro-
urokinase is more limited , and it is not known which of
these two natural activators at pharmacologic doses is most
effective, efficient and specific. Second, the use of com-
binations of rt-PA and pro-urokinase, which replic ate na-
turc's design . are only starting to be conside red .
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Pro-Urokinase
Fibrinolytic Properties
Pro-urokinase is a single chain precursor of classical,
two chain 55.000 M, urokinase. Although the latter has been
known since 1951 (6). pro-urokinase eluded detection until
1979 when it was first isolated and character ized (7.8). Pro-
urokinase has very different fibrinolytic properties from those
of urokinase in that it induces fibrin-specific clot lysis (9-1 1).
Fibrin selectivity comparable with that found in animals has
recently been reported from pilot studies in humans ( 12.13).
Although pro-urokinase and t-PA arc each fi brin-selective
activators of plasminogen. in most other respects they are
quite dissimilar and they induce fibrinolysis by different
mechanisms. A summary of certain properties that arc of
potential clinical interest are provided in Table I .
Antigenicity. Because pro-urokinase is an endogenous
protein like urokinase and t-PA. it has not been found to
be antigenic even at pharmacologic doses, in contrast to
streptokinase. The many years of clinical experience \vith
urokinase provide additional reassurance that antigenicity is
unlikely to be encountered. In contrast to t-PA. pro-uro-
kinase is a zymogen and is stable in plasma (14). Specifi-
cally, it does not form sodium dodecylsulfate-stable com-
plexes with inhibitors and its half-time to inhibition is > 72
hours (9) . However, despite its inert nature in blood, pro-
urokinase is rapidly cleared from the circulation and has a
clearance half-time that is similar to that of t-PA. This means
that the fibrinolytic effects of pro-urokinase will dissipate
promptly (within 15 minutes) after stopping an infusion.
Fibrin specificity. Although pro-urokinase was first iso-
lated because it had an affinity to fibrin/Celite greater than
that of urokinase (7,8). pro-urokinase does not have a fibrin
clot affinity comparable with that of t-PA. and the fibrin
specificity of pro-urokinase does not depend on fibrin bind-
ing. Rather , it appears to be related to a selective activation
of fi brin-bound plasminogen because of the latter' s confor-
rnational change (14) . These contrasting mechanisms of ac-
tion form the basis for their synergy (see later). Unlike
t-PA, pro-urokinase-induced clot lysis in vitro is associated
with a lag phase followed by a rapid second phase of lysis.
Table 1. Pro-Urokinase and Tissue-Type Plasminogen Activator
Comparison of Some Properties of Potential Clinical Relevance
Relative fibrin specificity
Nonantigenicity
Short in vivo half-time
Fibrin binding
Stability in plasma
Immediacy of onset
Inactivation by thrombin
Potentiation or nonspecificity by heparin
Pro-UK = pro-urokinase; t-PA = tissue-type plasminogen activator.
This lag phase has been attributed to the fact that virgin
fibrin has little plasminogen bound to it. providing little
substrate for pro-urokinase (15). After degradation has been
initiated, many new plasminogen binding sites are exposed
on fibrin ( 16) allowing pro-urokinase to become increasingly
more effective.
Inactivation by thrombin: lower tendency to bleeding.
Finally. pro-urokinase is very sensitive to inactivation by
thrombin ( 17) so that at a site of active hemostasis. where
thrombin is being generated, pro-urokinase will be promptly
neutralized. This may explain the seemingly lower tendency
to induce bleeding encountered in the preliminary clinical
investigations with pro-urokinase as compared with that re-
ported for rt-PA- induced thrombolysis (18) . Moreover,
nonspecific plasminogen activation by pro-urokinase is not
potentiated by heparin (unpublished observations) , whereas
heparin has been shown to bind both rt-PA and plasminogen
and thereby facilitate nonspecific plasminogen activation by
t-PA ( 19). Heparin and pro-urokinase have, in fact, been
infused simultaneously without complications (see later).
Clinical Studies of Pro-Urokinase
Preliminary studies. In six patients with acute coronary
thrombosis (12), 40 mg of pro-urokinase was infused over
60 minutes. followed by an additional 20 mg over 30 min-
utes in three of the patients. The infusion was associated
with reperfusion in four patients; significant fibrinogen deg-
radation occurred in one. The native pro-urokinase used in
the study contained about 5% urokinase. which may have
contributed to the fi brinogen degradation. In a second study
by Van de Werfet al. (13). 17 patients with acute Q wave
myocardial infarction were treated with nonglycosylated,
recombinant pro-urokinase expressed in Escherichia coli.
A total of 40 mg was infused in eight patients and it induced
incomplete coronary recanalization in six of them. In an
additional nine patients. infusion of 70 mg induced reca-
nalization with normal distal filling in seven. This was.
hov....ever. accompanied by 50% reduction in librinogen. It
has not yet been determined whether the fi brinolytic spec-
ificity of recombinant pro-urokinase is comparable with that
of native pro-urokinase.
Multicenter study. At the time of this writing. 11 0
patients with acute coronary thrombosis and infarction have
been treated with native pro-urokinase in the multicenter
dose-finding pilot studies being conducted by Sandoz Phar-
maceuticals in the United States and in West Germany. The
materia! used in these studies was purified from the culture
medium of a human kidney tumor cell line and has a mo-
lecular weight of approximately 54,000 . It migrates as a
single band on sodium dodecylsulfate-polyacrylamide gel
under reducing conditions and has an amidolytic activity
< 0.5% of its activated form, indicating that it contained
negligible urokinase contaminant. The manuscript (submit-
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Table 2. Pro-Urokinase (60 minute infusion) in 20 Cases of
Acute Coronary Thrombosis"
Dose No. With Time (min) to
Patient (mg) Reperfusion Reperfusion
Group I
4 15 :! 50. 60
) 22
3 30 2 60
I 60 1
9 55% 57
Group jv t
11 48.4 9 13 to 60
82% 30
'Unpublished observations of Kaspen ct al. Cited with permission.
t Bolus urokinase (200,000 IU) at onset. All patients received heparin
(1 ,250 units/h) for 24 hours. Rcocclusion at 24 hours: 0 of 18.
ted for publication) from one of the participating centers,
by Kaspar et al. of Freiburg , West Germany, has been
selected for summary with the kind permission of the prin-
cipal investigator, because it illustrates some findings of
special interest.
In the first phase of this study Crable 2) , a total dose
ranging from 15 to 60 mg was infused over I hour in nine
patients (Group I). This resulted in grade 3 (TIMI classi-
fi cation) coronary reperfusion in three patients and grade 2
reperfusion in an additional two patients, giving an overall
reperfusion rate of 55%. A relatively long time to reper-
fusion of 57 minutes was found. No fibrinogen degradation
occurred in this group. These overall findings are represen-
tative of the experience from the other centers. A high
degree of specifi city and no bleeding, but a relatively low
reperfusion rateand long time to rcperfusion, has been found
when 30 to 50 mg of pro-urokinase was infusedover I hour.
At doses of 70 rng/h, significant fibrinogen degradation has
been seen in some patients.
To improve the success rate and shorten the lysis time,
it was proposed by Dr. Welzel of Sandoz Numberg that a
bolus dose of urokinase (200 ,000 IU) he administered at
the outset. At this dose, urokinase has no demonstrable
independent effect. Among the subsequent II patients (Group
II) who received an infusion of 48.4 mg of pro-urokinase
over I hour after the urokinase bolus, grade 3 reperfusion
occurred in 9 patients and a mean time to clot lysis of 30
minutes was observed. Although Groups 1and II (Table 2)
cannot be considered comparable in that Group II received
a higher dose of pro-urokinase, the findings from the other
centers indicate that 50 mg of pro-urokinase is associated
with reperfusion in about 60 % of patients and 70 mg in
about 65%. with a mean time to lysis of about 45 minutes.
Taken together, these results suggest that the high lysis rate
and shorter lysis time found in Group II are attributable
more to the augmenting effect of urokinase on pro-
urokinase-induced thrombolysis than to differences in pro-
urokinase dosage. Moreover, subsequent to submission of
this manuscript, seven more patients have been treated to
date with this urokinase/pro-urokinase combination by Kas-
per et aI., bringing the total to 18 patients, of whom 15
(83%) had reperfusion at about 30 minutes.
The combination urokinase/pro-urokinase used in phase
1/ was accompanied by a 19% decrease in fibrinogen con-
centration at 60 minutes (p < 0.05) compared with baseline.
Of additional interest is that all patients in the Freiburg study
received simultaneous heparin (1 ,250 Uzh), which was con-
tinued for 24 hours (Table 2). Bleeding around a catheter
was reported in one of the patients. No other bleeding com-
plications were encountered. Repeat coronary angiography
was done at 24 to 48 hours in 18 of the patients, and no
evidence of reocclusion was found. This experience sug-
gests that the combination of high dose heparin with pro-
urokinase may offer a solution to the vexing problem of
rethrornbosis.
Mechanism for the Synergistic Effect of Urokinase
or of t-PA on Pro-Urokinase
The clinical findings from phase II of the multicenter
study summarized are supported by in vitro observations
that provide an explanation for the potentiating effect of
urokinase on pro-urokinase-induced thrombolysis. The
mechanism involved is believed to be similar to that pre-
viously proposed to account for the synergism between
100~
Figure I. A, Lysis of radiolabeled fi brin clots by 20
IUlml urokinase (0), 80 IV/ml pro-urokinase (X) or Clot
by a combination of urokinase and pro-urokinase (0). lysis
B. Clot lysis by 3 U/ml t-PA «». 40 IU/ml pro-
urokinase (X) or by a combination of t-PA and pro- 50
urokinase (0). A substantially greater than an ad-
ditive effect is apparent with both combinations. These
combinations also fulfilled the mathematical defini-
tion of synergy (sum of the fractional combinations
were < I, actually about 0.7) (20) .
A'--_.---_-.-_---,-_-.,._--, B'--_...,.-_-.-_---,__.--------,
2 3 4 5h 2 3 4 6h
]ACC Vol. 10. No. )
November 19~7 168-21B
(,LJREWICH
EXPERIENCES WITH PRO-UROKINASE
198
Figure 2. A, Lysis of radiolabeled fi-
brin clots by ]00 ng/ml pro-urokinase
(e) or by 50 ng/rnl t-PA (X). The
longer lag phase and steeper second
phase of lysis by pro-urokinase is ev-
ident. B, Lysis of clots preincubated
with t-PA (SOng/rnl) to promote bind-
ing. These clots wcre washed andthen
incubated in plasma containing 50
ng/rnl f-PA (X) or 300 ng pro-uroki-
nase (e). Marked potentiation of clot
lysis by pro-urokinase but not by the
additional t-PA is shown.
t-PA and pro-urokinase (15). A summary of these experi-
ments is included here because they are of potential clinical
importance and help interpret the observed promotion of
pro-urokinase efficacy by urokinase.
Comparison of synergistic effect of urokinase or t-PA
in pro-urokinase. The lytic effect of mixtures of urokinase
and pro-urokinase or of t-PA and pro-urokinase were com-
pared with the equivalent lytic effect of each activator alone
in a previously standardized clot lysis assay system (9) (Fig.
I). The potentiation of clot lysis by either urokinase or
t-PA on pro-urokinase obeyed Berenbaum's mathematical
definition of synergy (20). That is, the same thrombolytic
effect could be obtained by urokinase plus pro-urokinase or
by t-PA plus pro-urokinase at algebraic fractional combi-
nations < I (Fig. I). Moreover. the synergistic effect of
mixtures of urokinase or t-PA with pro-urokinase could be
reproduced when they were used sequentially rather than
simultaneously. Pretreatment of a clot by urokinase, or plas-
min followed by incubation of the washed clot with pro-
urokinase in fresh plasma, resulted in clot lysis comparable
with that obtained with simultaneous combinations of the
activators. This effect was attributed to the exposure of new
plasminogen binding sites on fibrin by plasmin generated
by pretreatment with urokinase.
Differences between the action of pro-urokinase and
rt-PA. By contrast, pretreatment of a fibrin clot with plas-
min did not potentiate clot lysis by t-PA, suggesting that
the plasminogen bound to the plasmin-exposed binding sites
on fibrin is susceptible to activation by pro-urokinase but
not by t-PA. This potentially important difference between
pro-urokinase and t-PA is further illustrated by the results
of another experiment (Fig. 2) that was designed to mimic
the effect of a bolus of t-PA followed by an infusion of pro-
urokinase. For this, clots were first exposed to t-PA (50
ng/ml of plasma) for I hour to provide time for binding of
rt-PA to fibrin. After washing. the clot was incubated in
fresh plasma with no additions, or with additional t-PA (50
ng/ml) or pro-urokinase (300 ng/rnl). The additional rt-PA
did not potentiate lysis over that induced by a single ex-
posure to t-PA at this same concentration. The added t-PA
evidently failed to augment the binding site occupancy of
t-PA already present on the preincubated clot. By contrast.
pro-urokinase induced marked potentiation of clot lysis rel-
ative to that induced by t-PA or pro-urokinase alone (Fig.
2b). The lytic effects of 50 ng t-PA and 300 ng of pro-
urokinase in this in vitro system were equivalent, although
t-PA dot lysis is relatively linear whereas that induced by
pro-urokinase is sigmoidal (Fig. 2a). The difference in the
dose requirements of t-PA and pro-urokinase to achieve
comparable clot lysis in vitro have not been found in vivo.
Other investigators have failed to find synergism between
t-PA and pro-urokinase in vitro (21) but have reported its
Figure 3. A virgin clot, represented at the upper left, contains
little fibrin-bound plasminogen. However. its lysis is effectively
initialed by l-PA. which appears to bind to a site close to the
available plasminogen (Pig). The resultant plasmin (Plm) induces
fibrin degradation. thereby exposing new plasminogen binding
sites. The plasminogen bound to these sites is activatable by pro-
urokinase but appears not to be accessible to t-PA. whereas the
plasminogen on the virgin clot is resistant to activation by pro-
urokinase. Clot lysis by the pro-urokinase-mediated pathway is
additionally accelerated by pro-urokinase activation to urokinase.
Oil the clot surface as shown. It is postulated that these comple-
mentary modes of action of [-PA and pro-urokinase illustrated
explain their synergism.
PIg" PIg" . Plm <, /Plg
Fibrin + l-PA _ Fibrin - . Fibrin --- Lysis
l-PA/ l-PA/ "'--Pig
+P-UK
/
Plm /Plg-P-UK
'Fibrin'
l-PA/ 'Plg-P-UK
/
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occurrence in vivo (22,23). The discrepancy in the in vitro
findings can be explained by differences in those experi-
mental conditions that arc essential for the demonstration
of synergy. These include a high molar ratio of pro-
urokinase to t-PA (::::-:5: I) and a pro-urokinase preparation
free of urokinase contamination , because the latter is itself
synergistic with pro-urokinase (24).
The apparent synergy, the contrasting shapes of the clot
lysis curves of t-PA (linear) and pro-urokinase (sigmoidal)
and the sharp differences in their fibrinolytic response to
pretreatment of fibrin with plasmin, urokinase or t-PA are
each expressions of dissimilar modes of action for t-PA and
pro-urokinase. More specifically, we have postulated from
these and other experimental findings that t-PA and pro-
urokinase have differentplasminogen substrates on the fibrin
clot (25). A schema illustrating this hypothesis according
to which t-PA and pro-urokinasearc complementary in their
fibrinolytic effect is shown in Figure 3.
An undegraded, virgin clot has little plasminogen bound
to it , probably because no terminal lysine residues are pres-
ent. The location of the plasminogen available is such that
it is accessible to activation by fibrin-bound t-PA, presum-
ably because the latter is bound to a neighboring region.
By contrast, experimental evidence indicates that this plas-
minogen is resistant to activation by pro-urokinase. The
plasmin generated by t-PA exposes new plasminogen-
binding sites on fi brin, as previously shown by Harpel et
al. (16). Once these new sites are occupied by plasminogen,
a conformational change is induced in the Glu-plasminogen
molecule, and it becomes susceptible to selective activation
by pro-urokinase (14,26). On the other hand, these new
plasminogen molecules appear to be inaccessible to acti-
vation by the fibrin-bound t-PA. Therefore, although clot
lysis by t-PA alone will go on to completion as illustrated,
it will be relatively inefficient and lysis will proceed much
faster if pro-urokinase is added. The latter bindsto the newly
available plasminogen and activates it. In the process, pro-
urokinase is converted to its more active derivative, uro-
kinase. as shown, which further accelerates local plasmin
generation and clot lysis. In short, t-PA is the trigger that
effic iently initiates lysis and prepares the fibrin for pro-
urokinase. which more effectively completes the lytic pro-
cess (Fig . 3).
Clinical implications, The proposed model for the com-
plementary and synergistic effects oft-PA and pro-urokinase
explains a number of clinical findings such as the high dose
requirements for t-PA and pro-urokinase whenthey are used
alone for thrombolysis. Blood concentrations that are about
I,OOO-foid higher than their physiologic concentrations are
being used in clinical trials. An explanation for this apparent
inefficiency is provided by the schema. The model also
explains the potentiation of pro-urokinase-induced throm-
bolysis by urokinase. The effect of urokinase mimics that
of t-PA in that it generates the same new plasminogen-
binding sites that are required for pro-urokinase. However.
because urokinase does not bind to fibrin and is rapidly
inactivated by inhibitors, its effect lTlay be anticipated to be
less efficient and less specific than that of t-PA. The po-
tentiating effect of urokinase on pro-urokinase also implies,
of course, that the urokinase contaminant in a pro-urokinase
preparation will alter its thrombolytic properties. Therefore,
not all pro-urokinase preparations can be assumed to be
equivalent in efficacy or specificity.
Conclusions
On the basis of limited clinical data but extensive lab-
oratory studies, some tentative conclusions may be ven-
tured: I) Pro-urokinase is a natural, plasminogen activator
that is nonantigeniceven at the pharmacologic dose and that
has a fibrin specificity comparable with that of t-PA. 2) Pro-
urokinase is rapidly inactivated by thrombin and its plas-
minogen activation is not potentiated by heparin; this may
account for an apparent lower incidence of bleeding com-
plications during thrombolysis compared with t-PA. 3) Pro-
urokinase clot lysis in vitro has a lag phase that may explain
an apparent lowerefficacy when pro-urokinase is used alone.
This lag phase can be attenuated by urokinase or t-PA and
is followed by a more rapid second phase. Although a sig-
moidal clot lysis curve has not been demonstrated in vivo,
the long reperfusion times found clinically with pro-
urokinase and the potentiation by urokinase are consistent
with a similar phenomenon occurring. 4) Pro-urokinase ap-
pears to be complementary in its mode of action to t-PA,
which seems to explain their synergy. 5) Thrombolytic ef-
ficacy, safety and economy arc apt 10 be better served by
the use of combinations of t-PA and pro-urokinase than by
either activator alone. The specific combination suggested
by the findings is that of a bolus injection of t-PA followed
by an infusion of pro-urokinase .
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